CG
TVRD

Cutler Group’s Tvardi Therapeutics TVRD Stock Holding History

Cutler Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17
Closed -$6K – 4885
2022
Q4 		$6K Hold
17
– – ﹤0.01% 3101
2022
Q3 		$5K Sell
17
-28
-62% -$10.1K ﹤0.01% 3719
2022
Q2 		$14K Buy
+45
New +$15.8K ﹤0.01% 2982
2022
Q1 		– Sell
-37
Closed -$15.2K – 6222
2021
Q4 		$16K Sell
37
-28
-43% -$14.1K ﹤0.01% 3325
2021
Q3 		$36K Buy
+65
New +$32.6K ﹤0.01% 2810
2020
Q3 		– Sell
-83
Closed -$51K – 5355
2020
Q2 		$51K Hold
83
– – ﹤0.01% 1738
2020
Q1 		$39K Buy
83
+66
+388% +$35.9K ﹤0.01% 1891
2019
Q4 		$9K Sell
17
-19
-53% -$13.3K ﹤0.01% 2721
2019
Q3 		$23K Sell
36
-39
-52% -$32.4K ﹤0.01% 2098
2019
Q2 		$57K Buy
75
+50
+200% +$35.1K 0.01% 1463
2019
Q1 		$17K Buy
25
+14
+127% +$8.38K ﹤0.01% 2162
2018
Q4 		$5K Sell
11
-11
-50% -$7.1K ﹤0.01% 2958
2018
Q3 		$19K Buy
22
+5
+29% +$3.61K ﹤0.01% 2286
2018
Q2 		$11K Sell
17
-77
-82% -$39.1K ﹤0.01% 2632
2018
Q1 		$42K Buy
94
+36
+62% +$17.5K ﹤0.01% 1788
2017
Q4 		$25K Sell
58
-6
-9% -$2.73K ﹤0.01% 2390
2017
Q3 		$31K Sell
64
-396
-86% -$198K ﹤0.01% 2721
2017
Q2 		$255K Sell
460
-18
-4% -$11.4K 0.01% 1099
2017
Q1 		$316K Sell
478
-223
-32% -$119K 0.01% 880
2016
Q4 		$234K Buy
701
+607
+646% +$195K 0.01% 1189
2016
Q3 		$28K Sell
94
-28
-23% -$6.07K ﹤0.01% 3096
2016
Q2 		$21K Sell
122
-50
-29% -$10.9K ﹤0.01% 3329
2016
Q1 		$38K Buy
172
+103
+149% +$30.8K ﹤0.01% 2613
2015
Q4 		$42K Buy
+69
New +$37.9K ﹤0.01% 2648

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutler Group's TVRD Position: Q1 2023 in Review

Cutler Group sold out of Tvardi Therapeutics (TVRD) in Q1 2023, closing a stake of 17 shares — an estimated $6K sold.

Cutler Group first reported a position in TVRD in Q4 2015 and held it in 24 quarters. The position peaked at $316K in Q1 2017. 162 funds tracked by Wall St. Rank hold TVRD as of Q1 2023.

  • Cutler Group reported no remaining Tvardi Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 17 Tvardi Therapeutics shares in Q1 2023, an estimated $6K.
  • Cutler Group first reported a position in Tvardi Therapeutics in Q4 2015 and held it in 24 quarters.
  • Cutler Group's Tvardi Therapeutics position peaked at $316K in Q1 2017.
  • 162 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.